Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
China (Chinese)
Profile Icon Profile Icon
登录/注册 UserName
产品

解决方案

发现&学习

资源&工具

Support

Search icon Search icon
Close Menu
      Alert Icon
      BUV615 Mouse Anti-Human CXCR6 (CD186)
      商品详情
      Down Arrow Up Arrow


      BD OptiBuild™
      C-X-C chemokine receptor type 6; BONZO; STRL33; TYMSTR
      Human (Tested in Development)
      Mouse BALB/c IgG2a, κ
      Human CXCR6
      Flow cytometry (Qualified)
      0.2 mg/ml
      10663
      AB_2875265
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      准备和存储

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      推荐的实验流程

      BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Note:  When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed.  For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).

      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      商品通知

      1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      2. Researchers should determine the optimal concentration of this reagent for their individual applications.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      9. CF™ is a trademark of Biotium, Inc.
      10. BD Horizon Brilliant Ultraviolet 615 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow
      751245 Rev. 2
      抗体详情
      Down Arrow Up Arrow
      13B 1E5

      The 13B 1E5 monoclonal antibody specifically binds to C-X-C chemokine receptor type 6 (CXCR6), which is also known as CD186, BONZO, T-lymphocyte-expressed seven-transmembrane domain receptor (TYMSTR), and Seven transmembrane receptor-like from clone 33 (STRL33). CXCR6 is a G-protein coupled chemokine receptor that is expressed on subsets of activated and memory T cells and NKT cells. CXCR6 binds to soluble CXCL16 and membrane-anchored CXCL16 expressed by dendritic cells and macrophages. The CXCL16 and CXCR6 interaction activates Akt and mTor signaling. This regulates cellular migration including the recruitment of tumor-infiltrating lymphocytes and may contribute to the progression and metastasis of various cancers. CXCR6 also can serve as a coreceptor for certain strains of HIV-1 and HIV-2.

      The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP.  Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).

      751245 Rev. 2
      格式详情
      Down Arrow Up Arrow
      BUV615
      The BD Horizon Brilliant™ Ultraviolet 615 (BUV615) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 615-nm. BUV615, driven by BD innovation, is designed to be excited by the ultraviolet laser (355 nm) and detected using an optical filter centered near 615-nm (e.g, 610/20 bandpass filter). The acceptor dye can be excited by the Blue (488-nm) and yellow-green (561-nm) lasers resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BUV615
      Ultraviolet 355 nm
      350 nm
      615 nm
      751245 Rev.2
      报价单和参考
      Down Arrow Up Arrow
      View product citations for antibody "751245" on CiteAb

      研发参考 (6)

      1. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses.. Nature. 1997; 388(6639):296-300. (Biology). 查看参考
      2. La Porta CA. CXCR6: the role of environment in tumor progression. Challenges for therapy.. Stem Cell Rev. 2012; 8(4):1282-5. (Biology). 查看参考
      3. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.. J Exp Med. 1997; 185(11):2015-23. (Biology). 查看参考
      4. Loetscher M, Amara A, Oberlin E, et al. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function.. Curr Biol. 1997; 7(9):652-60. (Biology). 查看参考
      5. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature.. Pharmacol Rev. 2002; 54(2):227-9. (Biology). 查看参考
      6. Xiao G, Wang X, Wang J, et al. CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms.. Oncotarget. 2015; 6(16):14165-78. (Biology). 查看参考
      查看所有文件 (6) 查看更少内容
      751245 Rev. 2

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.